Cerevel Therapeutics Holdings (Cerevel Therapeutics Holdings) Total Liabilities : $569.55 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Cerevel Therapeutics Holdings Total Liabilities?

Cerevel Therapeutics Holdings's Total Liabilities for the quarter that ended in Dec. 2023 was $569.55 Mil.

Cerevel Therapeutics Holdings's quarterly Total Liabilities increased from Jun. 2023 ($543.85 Mil) to Sep. 2023 ($549.00 Mil) and increased from Sep. 2023 ($549.00 Mil) to Dec. 2023 ($569.55 Mil).

Cerevel Therapeutics Holdings's annual Total Liabilities increased from Dec. 2021 ($110.19 Mil) to Dec. 2022 ($496.58 Mil) and increased from Dec. 2022 ($496.58 Mil) to Dec. 2023 ($569.55 Mil).

Cerevel Therapeutics Holdings Total Liabilities Historical Data

The historical data trend for Cerevel Therapeutics Holdings's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cerevel Therapeutics Holdings Total Liabilities Chart

Cerevel Therapeutics Holdings Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

42.98

60.75

110.19

496.58

569.55

Cerevel Therapeutics Holdings Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Liabilities	Get a 7-Day Free Trial												496.58	498.64	543.85	549.00	569.55

Cerevel Therapeutics Holdings Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Cerevel Therapeutics Holdings's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	92.179	+	(365.21	+	112.164
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	569.55

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	1243.298	-	673.745
	=	569.55

Cerevel Therapeutics Holdings's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	92.179	+	(365.21	+	112.164
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	569.55

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	1243.298	-	673.745
	=	569.55

Cerevel Therapeutics Holdings Total Liabilities Related Terms

Thank you for viewing the detailed overview of Cerevel Therapeutics Holdings's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Cerevel Therapeutics Holdings (Cerevel Therapeutics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cerevel Therapeutics Holdings Inc (NAS:CERE) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

673:Germany

Address

222 Jacobs Street, Suite 200, Cambridge, MA, USA, 02141

Website

https://www.cerevel.com

Cerevel Therapeutics Holdings Inc is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. It has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinson's disease and substance use disorder. Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions.

Executives

N Anthony Coles	director, officer: See Remarks	MORRIS CORP. CENTER I; BLDG. B; 4TH FLR., 300 INTERPACE PARKWAY, PARSIPPANY NJ 07054
Ramiro Sanchez	officer: Chief Medical Officer	C/O CEREVELL THERAPEUTICS HOLDINGS INC., 131 DARTMOUTH STREET SUITE 502, BOSTON MA 02116
Kenneth Dipietro	officer: Chief Human Resources Officer	C/O BIOGEN IDEC INC., 133 BOSTON POST ROAD, WESTON MA 02493
Susan Altschuller	officer: Chief Financial Officer	45 TENNYSON ST., SOMERVILLE MA 02145
Mark Bodenrader	officer: See Remarks	C/O CEREVEL THERAPEUTICS HOLDINGS INC., 131 DARTMOUTH STREET SUITE 502, BOSTON MA 02116
Kathleen Tregoning	officer: See Remarks	C/O CEREVEL THERAPEUTICS HOLDINGS, INC., 131 DARTMOUTH STREET SUITE 502, BOSTON MA 02116
Scott Akamine	officer: Chief Legal Officer	C/O AEON BIOPHARMA, INC., 4040 MACARTHUR BLVD., SUITE 260, NEWPORT BEACH CA 92660
Deval L Patrick	director	BAIN CAPITAL, LLC, 200 CLARENDON STREET, BOSTON MA 02116
Adam Koppel	director	C/O BROOKSIDE CAPITAL, LLC, JOHN HANCOCK TOWER, 200 CLARENDON ST, BOSTON MA 02116
Perceptive Life Sciences Master Fund Ltd	director	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Christopher R Gordon	director	C/O BAIN CAPITAL, LLC, JOHN HANCOCK TOWER, 200 CLARENDON STREET, BOSTON MA 02116
Bain Capital Investors Llc	10 percent owner	200 CLARENDON STREET, BOSTON MA 02116
Paul D. Burgess	officer: See Remarks	C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421
Renaud Ronald C Jr	director, officer: President & CEO	C/O IDENIX PHARMACEUTICALS, INC., 60 HAMPSHIRE STREET, CAMBRIDGE MA 02109
Marijn E Dekkers	director	GENERAL ELECTRIC COMPANY, 41 FARNSWORTH STREET, BOSTON MA 02210